Earnings call transcript: Nucleus Software falls as Q2 FY2027 profit slips

Nucleus Software’s Q2 FY2027 revenue rose 8.2% quarter on quarter to INR 227.7 crore ($24 million), while profit after tax fell 11% quarter on quarter and 19.2% year on year; EBITDA margin was 6.8%, down from 10.8% a year earlier. The order book increased to INR 1,317 crore, but higher AI and employee-related costs, longer implementation cycles and rising receivables weighed on profitability. Shares fell 4.8% to $621.25, about 2% above their 52-week low; management gave no formal guidance and said profitability could improve from FY2028, with timing uncertain.

Analysis

The key issue is not order-book growth but its conversion economics. Long, variable implementation cycles—and an undisclosed split between new licenses, projects and recurring maintenance—make the headline backlog a weak near-term earnings proxy. If conversion is delayed, elevated staffing and product investment depress margins for longer; if delivery productivity improves before hiring normalizes, operating leverage could be meaningful. Neither outcome is yet evidenced by this quarter.

The cost of that uncertainty is amplified by earnings quality: operating profitability remains below last year, while investment income contributes materially to reported profit. Cash reduces balance-sheet risk and makes an immediate financing-driven bear case less compelling, but rising receivables and DSO merit verification against subsequent collections; management’s timing explanation is not independently confirmed. A sustained deterioration would weaken the cash-flow case even if reported revenue grows.

For the next 1–3 months, focus on the next results and evidence of backlog conversion, collections and employee-cost control—not AI announcements. Over 6–18 months, AI is a two-sided factor: internal productivity could support margins, but incumbents such as Temenos, Oracle and Finastra can also use automation to defend delivery economics and intensify competition. The stock’s proximity to its annual low may already reflect a delayed recovery, so chasing a short is unattractive without fresh evidence. Conversely, a low multiple alone does not establish value when the margin-recovery date is uncertain.

Key Decisions for Investors

• Keep Nucleus Software at neutral/underweight rather than initiate an outright short after the sharp selloff. Reassess after the next results; require sequential margin improvement and cash conversion before adding risk.
• Treat backlog as a watch item, not an earnings catalyst, until the company provides better evidence of conversion. Track revenue growth alongside EBITDA margin, delivery costs and implementation progress; a growing book without improving revenue or margins falsifies the operating-leverage thesis.
• Verify whether the receivables increase was collected in the following quarter. Persistent elevated DSO or weaker operating cash flow would strengthen the downside case; normalization would reduce the near-term cash-quality concern.
• Do not pay for the AI narrative yet: look for measurable delivery productivity or margin benefit over coming quarters. The thesis is weakened if employee costs keep rising faster than revenue, or if management’s FY2028 recovery expectation slips; sustained margin recovery ahead of that timeline would be an upside catalyst.